Depatuxizumab Antibody

SKU: orb2278701

Description

Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).

Research Area

Cardiovascular Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	1471999-69-5
Purity	95.00%
Target	EGFR

Bioactivity

−

In Vivo

Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can significantly inhibit tumor growth in the U87MGde2-7 glioblastoma multiforme (GBM) model and A431 squamous cell carcinoma model of Nu/Nu mice. Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can inhibit tumor growth and pEGFR levels in the EGFRvIII-positive GBM-SN0199-PDX model of NSG mice.

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Disclaimer	For research use only

Alternative Names

−

ABT 806, ABT806, ABT-806, Depatuxizumab

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Quick Database Links

Gene Symbol

EGFR

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols